Publications by authors named "Chun-Long Yan"
Relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/LBL) are frequently aggressive and associated with unfavorable prognoses. Pan-targeted Chimeric Antigen Receptor (CAR) T-cell therapy have shown promising results in clinical trials. In recent years, CD7 CAR T-cell and CD5 CAR T-cell demonstrate effectiveness in treating r/r T-ALL/LBL patients with bone marrow infiltration.
View Article and Find Full Text PDFArticle Synopsis
- Severe cytokine release syndrome (sCRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) hinder the use of CAR T-cell therapy, prompting researchers to develop a new CAR (ssCART-19) that incorporates shRNA to target the IL-6 gene.
- In a study involving 87 patients with relapsed/refractory B-cell acute lymphoblastic leukemia, ssCART-19 demonstrated significantly lower rates of grade ≥3 CRS (14.89%) and ICANS (4.26%) compared to conventional CAR T-cells (cCART-19) which had rates of 37.5% and 15%, respectively.
- Overall response rates and survival metrics were comparable
Background: The transforming growth factor β (TGFβ) signaling pathway plays a crucial role in the development of liver fibrosis by activating TGFβ type II receptor (TGFβR2), followed by the recruitment of TGFβR1 finally triggering downstream signaling pathway.
Aim: To find drugs targeting TGFβR2 that inhibit TGFβR1/TGFβR2 complex formation, theoretically inhibit TGFβ signaling pathway, and thereby ameliorate liver fibrosis.
Methods: Food and Drug Administration-approved drugs were screened for binding affinity with TGFβR2 by virtual molecular docking.
Environmental temperature serves as a major driver of adaptive changes in wild organisms. To discover the mechanisms underpinning cold tolerance in domestic animals, we sequenced the genomes of 28 cattle from warm and cold areas across China. By characterizing the population structure and demographic history, we identified two genetic clusters, i.
View Article and Find Full Text PDF